Providing independent clinical excellence since 2005
Posted on Saturday September 13, 2025 in Metabolic Health
An article written by Dr Edward Leatham, Consultant Cardiologist
Tags: VAT, GLP-1, Inflammation, Diet, Arthritis, search website using Tags to find related stories.
For busy people, or to tune in when on the move, Google Notebook AI audio podcast and an explainer slide show are available for this story beneath.
Joint pain—hips, knees, back, fingers, hands—is a common complaint in overweight and obese individuals. Traditionally, improvements in joint symptoms following weight loss have been attributed to reduced mechanical load: less weight equates to less strain on load-bearing joints. But increasingly, both clinical observations and scientific evidence suggest another mechanism may be at play.
Adipose tissue—particularly visceral adipose tissue (VAT)—is not merely a passive energy store. It is metabolically active and pro-inflammatory, secreting cytokines and adipokines that drive systemic inflammation. It is therefore plausible that reducing VAT may alleviate joint pain by lowering inflammatory signalling, not just mechanical stress.
In this article, we explore the hypothesis that weight loss reduces arthritis and joint pain by lowering inflammatory mediator release from VAT, rather than load-bearing mechanics alone.
VAT is biologically distinct from subcutaneous fat. It is more vascularised, more innervated, more densely infiltrated with immune cells (especially macrophages), and more prone to hypoxia and fibrosis. Importantly, VAT secretes a range of inflammatory cytokines—such as IL-6, TNF-α—and adipokines like leptin and resistin, which perpetuate systemic inflammation and may directly impact joint tissues¹.
These molecules are now recognised as key drivers of chronic, low-grade inflammation seen in metabolic syndrome, and are increasingly implicated in the development and progression of osteoarthritis (OA)².
Several population-based and imaging studies suggest that central obesity, especially visceral fat, correlates more strongly with joint pain than body mass index (BMI) alone.
These studies collectively indicate that VAT—not just overall adiposity—is closely linked with both inflammatory signalling and symptomatic joint disease.
Inflammatory mediators secreted by VAT—such as IL-6, TNF-α, and leptin—have been shown to:
Animal models further support this pathway. In high-fat diet–induced obesity models, mice developed accelerated OA with increased cartilage erosion and synovial thickening. Importantly, these changes correlated with increases in circulating IL-6 and TNF-α⁶.
Furthermore, adipokines like leptin can act directly on cartilage and bone cells, altering metabolism and promoting catabolic activity in joint tissues⁷.
Most clinical evidence comes from studies on knee osteoarthritis, where both mechanical load and inflammatory processes play a role.
A 2020 study by McLeod et al. examined dietary weight loss and exercise interventions. They found that VAT loss, more than total weight loss, correlated with reductions in CRP, an acute-phase marker of systemic inflammation¹⁰.
Another meta-analysis by Bulmer et al. (2025) showed reductions in IL-6 and TNF-α in some—but not all—weight loss studies, pointing to variability in individual responses and fat loss localisation¹¹.
These findings reinforce the idea that loss of VAT, rather than total weight, is critical in reducing systemic inflammatory burden.
GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide offer a new tool in obesity management. Beyond weight loss, they target visceral fat preferentially, reduce appetite, and may have direct anti-inflammatory effects.
Experimental models indicate that GLP-1 RAs reduce macrophage infiltration in VAT, suppress IL-6 and TNF-α production, and improve insulin sensitivity. This systemic anti-inflammatory shift could theoretically reduce joint inflammation, particularly in OA⁶.
A 2022 review by Meurot et al. proposed that GLP-1 may modulate synovial cell activation, suppressing catabolic cytokine release in joints¹².
While most trials focus on knee OA, patients in real-world settings report improvements in:
However, randomised data for these joints is lacking, and observational findings need confirmation through dedicated trials.
We propose the following model:
The following evidence supports this:
| Supported Findings | Areas Needing Clarification |
|---|---|
| VAT correlates with OA and joint pain⁴⁵ | Lack of RCTs in non-knee joints |
| GLP-1 RA therapy reduces pain independent of weight loss 8,12 | Contribution of specific cytokine changes needs better quantification |
| VAT loss correlates with lower CRP¹⁰ | Less consistent effects seen with IL-6, TNF-α in long-term studies¹¹ |
| Animal models show VAT inflammation worsens OA⁶ | Human joint imaging studies linked to VAT loss are lacking |
To better validate and apply this hypothesis, the following are needed:
Weight loss remains one of the most effective non-invasive treatments for joint pain. But it’s time to move beyond the mechanical load hypothesis.
Emerging evidence shows that visceral fat is a pro-inflammatory endocrine organ, and that its reduction through GLP-1 therapy or caloric restriction leads to decreased cytokine production and systemic inflammation. This may explain improvements in joint symptoms—even in non-load-bearing joints like the fingers and spine.
While more mechanistic and interventional studies are needed, targeting VAT to reduce joint pain is a promising and actionable concept for both clinicians and patients.
If you’re taking GLP-1 mimetics like Mounjaro, Ozempic, or Wegovy, you’re receiving a legitimate, medically prescribed therapy. Just like someone with asthma carries an inhaler, or a diabetic uses insulin, there’s no shame in needing a jab to support your metabolic health. Whether you are travelling or attending a hospitality event, here are some tips on how to navigate these new waters.
Mammalian hearts, including humans, feature two atria - the left and the right. These chambers serve as reception areas, collecting blood before it's dispatched to the ventricles. This system bears a resemblance to a turbocharger in an engine, where the atria boost the heart's efficiency, preparing it for a powerful contraction.
Continuous glucose monitoring offers a valuable tool for anyone concerned with their long-term health, especially those with a family history of diabetes or other cardiovascular risk factors. Whether through self-monitoring or professional analysis such as our metabolic health assessment, CGMs can provide actionable insights that help individuals manage their glucose levels more effectively, ultimately contributing to a healthier, longer life. By understanding and managing your glucotype, optimising your diet and exercise, and taking steps to prevent prediabetes and diabetes, you can potentially avoid serious health conditions in the future.